Hot Investor Mandate: Growth Equity Firm Invests Up to $20M in Therapeutics and Medical Device Companies, Starting From Series A Rounds

16 Dec

A venture capital and growth equity firm making investments in life sciences will invest as early as Series A and through growth transactions and is currently investing out of their second fund. The firm looks to invest between $10-20M per investment. The firm is looking for companies with clinical data and/or commercial products. The firm has a preference for funding companies that are repurposing existing approved technologies for new indications. The firm is willing to invest in therapeutics, medical device and diagnostics companies.

The firm has a primary focus on pharmaceuticals / therapeutics, and a secondary focus on medical devices. The firm is agnostic to indication.

The firm plays an active role in their portfolio companies. The firm will take a board seat with any company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Cross-Border Investment Firm Invests Up to $10M in Therapeutics and Devices With Strong Interest in Technologies with China Market Potential

16 Dec

A venture capital firm founded in 2016 is focused on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. Currently, the firm is partnered with the Chinese Government to bring good projects from North America to China and are focused on technologies that are at an advanced stage with patents that are willing to launch in Chinese markets or to set up factories and labs in China. The firm is however, willing to invest smaller amounts in good opportunities that have no interest/fit for the Chinese markets as well. The firm’s major focus within the life sciences is biotech and is focused on seed to series B rounds. The firm generally invests up to $10M USD for Series A deals, is flexible for series B rounds, and invests up to $1M USD for seed stage rounds.

Within the Life Sciences space, the firm is specifically focused on clinical tests, therapeutics, and other biotech technologies. The firm is also interested in medical devices focusing on large disease areas within China such as diabetes and cancer. Additionally, the firm is focused on technologies within these sectors that have a good fit with the Chinese Market or have a strong interest in working in China.

When investing, the firm looks to take a board seat. The firm provides consulting, localization services, and the ability to leverage resources in China to help the company grow alongside their direct equity investment and believe that these abilities can be best leveraged with a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm Primarily Invests Up to $10M in USA and Europe, Most Interested in Tech-Based Diagnostics, Life Science Tools, Digital Health Companies

16 Dec

A venture capital firm is looking to invest in tech-based digital health and diagnostics companies looking to expand to the Chinese market. The firm primarily invests in European companies, but will consider companies based in the US as well. The firm looks to leverage their connections to China and the Chinese market on behalf of its portfolio companies. The firm looks to invest between $2-10M in companies, taking a 15-30% equity stake. The firm prefers to be a lead investor, taking an active role in their portfolio companies, and will invest in about 2 companies a year, depending on their fund cycle. In cases where the firm does not invest funds, they are also willing to offer consulting services for equity, connecting companies with strategic partners in China.

The firm has an additional partnership model that, instead of direct investment, licenses technologies through a Chinese platform company, acting as a focused distributor for entry into the Chinese market. This is the firm’s alternate investment approach to bringing these technologies to the Chinese market, by utilizing this Chinese platform company to serve as their portfolio company’s representative in China to navigate the regulatory environment and spearhead all of the sales and marketing.

The firm is interested in tech companies that are not consumer focused. The firm looks for companies such as diagnostics tools or AI/machine learning technologies in the healthcare space. The firm has some experience with pathology diagnostic related companies, but is willing to consider other areas as well. The firm prefers to invest in a few companies within the same area, choosing complementary technologies between their portfolio companies. The firm will consider companies with technologies that are in development or in pilot stages.

The firm is an active investor and takes a board seat for every company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe-Based VC Firm Has Interests in All Life Science/Healthcare Related Technologies, With Strongest Interest in Advanced Therapies

16 Dec

A venture capital firm headquartered in Western Europe closed their first fund in 2012 and the portfolio companies have advanced into clinical stages, raised additional funding and one of the companies has recently completed an exit. The firm recently raised a second fund for Pre-Seed, Seed, and Series A investments with a focus in technology transfer in all four life science sectors. The firm invests €1-2M as a seed investment in the form of equity or convertible notes to help companies advance into preclinical proof of concept, and can continue investing up to €6M. If additional funds are needed, the firm seeks co-investments from the strong network of investors they have in Europe. The firm is also looking to expand this network into the US as well. The firm is looking for investments across Europe.

The firm invests in all four life science sectors, but has a particular focus on therapeutics. Within therapeutics the firm has an interest in cutting edge technologies in advanced therapies, gene and cell therapy, gene editing and synthetic biology. The firm is agnostic to subsector and indication and will invest in pre-clinical companies and follow the companies through the development of the project with additional investors. The firm is open to all 3 classes of medical devices.

The firm looks for companies with a scientific founder, and preferably a C Level executive with a track record in biotech or pharmaceutical companies. The firm prefers to lead or co-lead in Seed stage therapeutics companies and will seek a board seat. The firm will co-invest in medtech investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Pitching at Digital RESI JPM

9 Dec

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

It has been more than a year since we’ve introduced the Innovator’s Pitch Challenge (IPC), Life Science Nation’s latest effort to boost exposure for early-stage companies attending the Redefining Early Stage Investment (RESI) conference virtually. Since its inception, the IPC has become one of the most anticipated components of the RESI program. To date, hundreds of early-stage life science and healthcare startups and hundreds of investor and industry expert judges have participated. We are excited to continue growing this dynamic platform of companies and investors, strategic partners, industry experts, and more to facilitate new conversations.

Hear from some of these previous participants about their experience and how the IPC helped them along their fundraising journey:

We are actively accepting applications for the Digital RESI JPM Innovator’s Pitch Challenge, where we will showcase innovative technologies across therapeutics, medical devices, diagnostics/tools, and digital health.

Applications are due Friday, December 17 – it’s not too late to apply!

Apply for IPC with Icon

Showcase Your Brand to Life Science Startups at Digital RESI JPM

9 Dec

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

Life science startups face a myriad of unique challenges due to the complexity of the healthcare system, including potentially years-long paths to market, regulatory hurdles, and possible reimbursement issues. All of these areas, among others, present opportunities for service providers to lend their expertise, preventing startups from costly mistakes that could prevent their products from reaching the market due to reasons other than a failure in the technology.

While connecting startups with investors is a large part of our work, Life Science Nation has also emphasized the importance of the presence of service providers at our Redefining Early Stage Investment (RESI) conferences.  RESI’s unique partnering platform allows attendees to filter the companies by sector, indication, and stage of development, among other criteria, so your target leads will be just a few clicks away.

While RESI partnering provides a powerful avenue to identify new clients, service providers that attend RESI have the option of multiple levels of participation, improving their exposure beyond that generated by partnering outreach. This can include:

Hosting a 1-hour live workshop to introduce your service

  • Open to all registered RESI attendees
  • The recording will be posted on the sponsor dedicated webpage (a virtual exhibition table) at RESI live agenda for a month, during which you can expect some attendees to contact you in partnering (Check Out an Example Here: McDermott Will & Emery)
  • After the conference, a detailed report on the workshop audience will be provided

Get a spotlight on Life Science Nation’s Weekly Newsletter, with a readership of 50,000+

Interested in learning more about the opportunities available at RESI? Make sure to check out the full sponsorship brochure below!

The Omicron Effect: What May Change and What Won’t

9 Dec

By Rory McCann, Marketing Manager & Conference Producer, LSN

It seems like not much time has passed since events around the world opened back up for in-person attendance. However, with the emergence and spread of the Omicron variant of COVID-19, many who had enthusiastically jumped back into in-person networking are asking, “What now?”

Whether discussing COVID-19 or fundraising in general, there is no crystal ball, leaving many to wander around in the dark hoping to make the most of uncertain times. In the absence of future forecasting, what I can offer instead are principles of partnering that are consistent and productive, no matter the state of the world around you.

Partnering is a numbers game, but not one of luck. Success takes research, strategy, patience, follow-up, and the ability to take feedback constructively. To prove that these aren’t new principles, check out these past interviews and articles outlining what successful partnering looks like. The truth is that there is no perfect environment for fundraising. Whether the Omicron variant throwing a wrench into the best-laid plans of in-person meetings or another event that gets in the way, solid principles will carry into successful partnering and lead to powerful partnerships in the future.

Learn more about how Life Science Nation can help you with your fundraising efforts and check out the newest digital  Redefining Early Stage Investment (RESI) conference, January 11-13. Early bird rates apply until December 17!

← Older Entries
Newer Entries →